newsfilter
← Latest News
GlobeNewswire·

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

  • The FDA approved Livsayis (cemdisiran) on November 18, 2026, for treating anti-AChR antibody-positive generalized myasthenia gravis (gMG) in adults.
  • Livsayis is Regeneron's first approved siRNA therapy & first approved neurology medicine, & the only FDA-approved gMG treatment administered subcutaneously four times a year.
  • Approval was based on Phase 3 NIMBLE trial results showing rapid, deep, & sustained disease control maintained throughout three-month dosing intervals.
  • At 24 weeks, Livsayis demonstrated a 4.5-point improvement on the MG-ADL score compared to 2.2 points with placebo, representing a 2.3-point placebo-adjusted improvement.
  • At 24 weeks, Livsayis showed a 4.2-point improvement on the QMG score compared to 1.5 points with placebo, representing a 2.8-point placebo-adjusted improvement.
  • Clinically meaningful benefit on the MG-ADL scale was observed as early as two weeks after starting treatment.
  • Livsayis is a C5-directed siRNA that reduces circulating C5 protein levels to limit terminal complement activation, a key driver of AChR-positive gMG.
  • The prescribing information includes a Boxed Warning for serious meningococcal infections, requiring vaccination at least two weeks prior to the first dose.
  • Livsayis is available only through a restricted REMS program that mandates provider enrollment, patient counseling, vaccination verification, \& distribution of a Patient Safety Card.
  • Common adverse reactions occurring in ≥5% of patients more frequently than placebo included injection site reactions, viral infections, & urinary tract infections.
  • A regulatory submission for Livsayis in the European Union is under review with a decision expected in the second half of 2027.
  • Regulatory submissions are planned for additional markets, including Japan.
  • Regeneron's myRARE™ program provides resources for patients & providers regarding product information, insurance verification, \& financial support.
Company
Regeneron Pharmaceuticals, Inc.
Keywords
Nasdaq:REGN, Regeneron Pharmaceuticals, Inc.